GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Basic Sciences/Oral Microbiome Dysbiosis and Precancerous Lesions of the Upper GI Tract

Oral Microbiome Dysbiosis and Precancerous Lesions of the Upper GI Tract

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated August 1, 2025

Quick Answer

The study highlights the relationship between oral microbiome dysbiosis and the development of precancerous lesions in the upper gastrointestinal (GI) tract. Dysbiosis refers to an imbalance in the microbial community, and in this context, it is associated with various upper GI disorders that may precede cancer, such as reflux, esophagitis, Barrett’s esophagus, and gastric conditions like atrophic gastritis.


The study highlights the relationship between oral microbiome dysbiosis and the development of precancerous lesions in the upper gastrointestinal (GI) tract. Dysbiosis refers to an imbalance in the microbial community, and in this context, it is associated with various upper GI disorders that may precede cancer, such as reflux, esophagitis, Barrett’s esophagus, and gastric conditions like atrophic gastritis.

### Key Findings:

1. **Salivary Dysbiosis:**

  • Imbalances in the salivary microbiome were linked to conditions such as reflux, esophagitis, Barrett’s esophagus, and other gastric disorders.
  • Saliva serves as a general indicator of systemic and upper GI health.

2. **Site-Specific Dysbiosis:**

  • Dysbiosis in the subgingival (below the gumline) and buccal mucosal (inner cheek) microbiomes was more specifically associated with Barrett’s esophagus and atrophic gastritis.
  • These site-specific microbial changes suggest that the oral microbiome's composition varies depending on the disease and its location.

3. **Microbial Signatures:**

  • Disease states were characterized by an **enrichment of harmful bacteria** like *Prevotella*, *Fusobacterium*, and *Fretibacterium*.
  • There was also a **depletion of protective bacteria** such as *Haemophilus*, which are thought to contribute to maintaining oral and systemic health.

4. **Cancer Risk Prediction:**

  • Among the oral microbiomes studied, the **subgingival microbiota** demonstrated the greatest potential as a biomarker for predicting cancer risk.
  • This suggests that microbial imbalances in subgingival sites might be early indicators of esophageal and gastric cancer development.

### Implications:

  • **Non-Invasive Biomarkers:** The findings support the development of non-invasive diagnostic tools based on oral microbiome analysis. This could enable early detection of esophageal and gastric cancers, improving patient outcomes.
  • **Targeted Interventions:** Understanding the specific microbial changes associated with different precancerous lesions may allow for targeted prevention strategies, such as microbiome modulation through probiotics, oral hygiene practices, or dietary changes.

### Conclusion:

The study underscores the importance of the oral microbiome in the pathogenesis of upper GI tract disorders and its potential role in cancer risk assessment. Site-specific dysbiosis, particularly in the subgingival microbiota, offers promising avenues for developing early detection methods and preventive measures for esophageal and gastric cancers.

Related Q&A

ARID1A Loss Drives ICC Development: Hepatology | June 2026

Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...

Blocking Succinate–GPR91 Signaling in MASH: Hepatology | April 2026

Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...

THRSP–MIF Signaling Drives MASH Progression: Hepatology | April 2026

Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...

Butyrate and Butyrate-Producing Bacteria in CKM: Antioxidants | July 2026

Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...

CK7, CK20, and CDX2 Refine Prognosis in Small Intestinal Adenocarcinoma: Annals of Oncology | 2026

• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...

Fatty Liver Drives Hyperglycemia Through Liver–Gut Signaling : Cell Metab | Jun 2026

Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer